Literature DB >> 19931492

Cognition across the lifespan: antiepileptic drugs, epilepsy, or both?

Bruce Hermann1, Kimford J Meador, William D Gaillard, Joyce A Cramer.   

Abstract

Cognitive problems in persons with epilepsy manifest over a lifetime; however, whether abnormal cognition in an individual with epilepsy is a result of comorbid brain substrate, the epilepsy itself or its underlying etiology, the antiepileptic agents used to control it, or a combination of these and other factors remains controversial. There is a continuing need for improved therapies to control seizures and reduce the incidence of adverse events, especially those involving the central nervous system that compromise attention, intelligence, language skills, verbal and nonverbal memory, executive function, and psychomotor speeds. Although cognitive decline typically occurs among patients with more severe epilepsy, physicians must judiciously select therapy with an eye toward not only controlling seizures but also ensuring that all patients retain as much function as possible throughout their lives. 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19931492     DOI: 10.1016/j.yebeh.2009.10.019

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  29 in total

Review 1.  Cognitive impairment in epilepsy: the role of network abnormalities.

Authors:  Gregory L Holmes
Journal:  Epileptic Disord       Date:  2015-06       Impact factor: 1.819

2.  Methylphenidate: Brain Gain for the Epilepsy Drain.

Authors:  Jong Woo Lee
Journal:  Epilepsy Curr       Date:  2017 May-Jun       Impact factor: 7.500

3.  Investigation of altered microstructure in patients with drug refractory epilepsy using diffusion tensor imaging.

Authors:  Yuwei Jiang; Lingyan Mao; Xu Yan; Mingxia Fan; Xin Wang; Jing Ding; Dongrong Xu
Journal:  Neuroradiology       Date:  2017-04-25       Impact factor: 2.804

4.  Cognitive Outcome in Childhood-Onset Epilepsy: A Five-Decade Prospective Cohort Study.

Authors:  Mira Karrasch; Petri Tiitta; Bruce Hermann; Juho Joutsa; Shlomo Shinnar; Juha Rinne; Anu Anttinen; Matti Sillanpää
Journal:  J Int Neuropsychol Soc       Date:  2017-01-10       Impact factor: 2.892

5.  Antiepileptic drug effects on subjective and objective cognition.

Authors:  Robert J Quon; Morgan T Mazanec; Samantha S Schmidt; Angeline S Andrew; Robert M Roth; Todd A MacKenzie; Martha Sajatovic; Tanya Spruill; Barbara C Jobst
Journal:  Epilepsy Behav       Date:  2020-01-29       Impact factor: 2.937

6.  Antiseizure drugs differentially modulate θ-burst induced long-term potentiation in C57BL/6 mice.

Authors:  Peter J West; Gerald W Saunders; Gregory J Remigio; Karen S Wilcox; H Steve White
Journal:  Epilepsia       Date:  2014-01-21       Impact factor: 5.864

7.  High seizure load during sensitive periods of development leads to broad shifts in ultrasonic vocalization behavior in neonatal male and female C57BL/6J mice.

Authors:  Suzanne O Nolan; Samantha L Hodges; Siena M Condon; Ilyasah D A Muhammed; Lindsay A Tomac; Matthew S Binder; Conner D Reynolds; Joaquin N Lugo
Journal:  Epilepsy Behav       Date:  2019-04-22       Impact factor: 2.937

8.  Integration of gray matter nodules into functional cortical circuits in periventricular heterotopia.

Authors:  Joanna A Christodoulou; Mollie E Barnard; Stephanie N Del Tufo; Tami Katzir; Susan Whitfield-Gabrieli; John D E Gabrieli; Bernard S Chang
Journal:  Epilepsy Behav       Date:  2013-10-03       Impact factor: 2.937

9.  The brain, seizures and epilepsy throughout life: understanding a moving target.

Authors:  Tallie Z Baram
Journal:  Epilepsy Curr       Date:  2012-07       Impact factor: 7.500

10.  Understanding relationships between autism, intelligence, and epilepsy: a cross-disorder approach.

Authors:  Agnies M van Eeghen; Margaret B Pulsifer; Vanessa L Merker; Ann M Neumeyer; Elmer E van Eeghen; Ronald L Thibert; Andrew J Cole; Fawn A Leigh; Scott R Plotkin; Elizabeth A Thiele
Journal:  Dev Med Child Neurol       Date:  2012-12-04       Impact factor: 5.449

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.